Pacira Biosciences, Inc.

Registration Deadline:

03/14/2025

A securities class action has been filed in the USDC – N.J., against Pacira Biosciences, Inc. (PCRX) (“Pacira” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Pacira common stock between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”).

 

Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions. 21. The Company currently offers three commercial-stage non-opioid treatments, including Exparel, Zilretta, and iovera. Pacira describes Exparel as a treatment that utilizes the Company’s unique and proprietary multivesicular liposome delivery technology that encapsulates drugs without altering their molecular structure and releases them over a sustained period.

 

The claim arises on August 9, 2024, when Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

The complaint alleges that Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Pacira’s Exparel patent scope and protections; pertinently, Pacira concealed or otherwise minimized the significance of the New Jersey District Court’s holding regarding claims construction and Pacira’s attempt to submit new evidence, including exhibits and findings of fact to the Court, which the Court considered and rejected. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Pacira’s securities at artificially inflated prices.

 

Following this news, Pacira’s common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira’s stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day.

 

If you purchased Pacira common stock during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

 

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.